Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB:ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Interleukin Genetics’ lead products include its proprietary ILUSTRA Inflammation Management Program, a turnkey program that utilizes a simple genetic test to easily identify patients at elevated risk for developing severe periodontal disease, due to a genetic tendency to over-produce inflammation, and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.